CAPR - NASDAQ

Capricor Therapeutics, Inc.

CAPR·NASDAQ

$28.29

+3.5%

HealthcareBiotechnology

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.29B

EPS-2.2600

P/E Ratio-12.52

Earnings Date08/11/2026

0.00

Revenue

-100%

3Y-100.0%

5Y-100.0%

10Y-100.0%

-105.04M

Net Income

160%

3Y+262.0%

5Y+669.0%

10Y+459.0%

-69.81B

Operating Cash Flow

174447%

3Y-1419999.0%

5Y+694207.0%

10Y+441698.0%

Capricor Therapeutics, Inc. Profit Bridge

CAPR · NASDAQ

Revenue & Cost of Sales

Revenue0.00

Cost of Goods Sold (0.00)

Gross Profit0.00

Operating Expenses

Operating Expenses (108.14M)

Operating Income-108.14M

Other Income & Taxes

Interest Expense (3.05M)

Other Income/Expense3.10M

Pretax Income-105.04M

Income Tax (0.00)

Net Income-105.04M

Net Income

-105.04M

Profitability Analysis

Capricor Therapeutics, Inc. Income Statement

CAPR • NASDAQ

Capricor Therapeutics, Inc. Income Statement	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
REVENUE
Revenue	0.0	22.3M	25.2M	2.6M	244.9K	310.3K	1M	1.7M	2.7M	3.2M	3.8M	4.2M	503.2K	195.5K	1.4M	0.0	0.0	0.0	101.4K	380.8K
GROSS PROFIT
Cost of Revenue	(0.0)	(50M)	(36.4M)	(21.8M)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Gross Profit	0.0	-27.7M	-11.3M	-19.3M	244.9K	310.3K	1M	1.7M	2.7M	-12M	-8.2M	-3M	503.2K	195.5K	1.4M	0.0	0.0	0.0	101.4K	380.8K
OPERATING INCOME
Operating Expenses	(108.1M)	(14.9M)	(12.8M)	(10.4M)	(21.2M)	(14M)	(8.7M)	(17M)	(4.8M)	(4.9M)	(4.4M)	(10.2M)	(7.4M)	(2.6M)	(6.3M)	(6.3M)	(7.7M)	(13.4M)	(9.6M)	(12.1K)
Selling, General & Administrative	(23.7M)	(14.9M)	(12.8M)	(10.4M)	(7.6M)	(5.5M)	(3.6M)	(4.9M)	(4.8M)	(4.9M)	(4.4M)	(3M)	(2.2M)	(1.6M)	(2.1M)	(2.2M)	(3.4M)	(3.9M)	(4.5M)	(179.2K)
Research & Development	(84.5M)	(50M)	(36.4M)	(21.8M)	(13.6M)	(8.5M)	(5.1M)	(12.1M)	(10.8M)	(16M)	(13.8M)	(7.8M)	(5.2M)	(1M)	(4.1M)	(4.1M)	(4.5M)	(9.5M)	(5.1M)	(2.7M)
Operating Income	-108.1M	-42.6M	-24.1M	-29.7M	-20.9M	-13.7M	-7.7M	-15.3M	-12.9M	-17M	-12.6M	-6M	-6.9M	-2.4M	-4.9M	-6.3M	-7.9B	-13.4B	-9.5M	-2.5M
PRE-TAX INCOME
Interest Expense	(3M)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(398.8K)	(344.7K)	(248.6K)	(200.5K)	(58.1K)	(0.0)	(0.0)	(0.0)	(0.0)	(137.0)	(1.1M)	(950.0)
Net Interest Income	3.2M	2.2M	1.7M	521.5K	0.0	0.0	0.0	0.0	-398.8K	-344.7K	-248.6K	-200.5K	0.0	0.0	6K	0.0	0.0	332.6K	-1.1M	-950.0
Other Expenses	(0.0)	-50M	-36.4M	-21.8M	(0.0)	(0.0)	(0.0)	(0.0)	-10.8M	-809K	-1.7M	-620K	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Total Other Income Expenses Net	3.1M	2.1M	1.8M	677.9K	915.9K	32.9K	92.1K	136K	15.3M	-1.8M	-246K	-199K	-2M	545.9K	14.4M	262.1K	11.4K	268.4K	9.5M	2.5M
Income Before Tax	-105M	-40.5M	-22.3M	-29M	-20M	-13.7M	-7.6M	-15.2M	2.4M	-18.8M	-12.9M	-6.2M	-8.9M	-1.9M	-4.9M	-6M	-7.9M	-13.1M	0.0	0.0
NET INCOME
Income Tax Expense	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	-11.4K	-268K	(0.0)	(0.0)
Net Income	-105M	-40.5M	-22.3M	-29M	-20M	-13.7M	-7.6M	-15.2M	2.4M	-18.8M	-12.9M	-6.2M	-8.9M	-1.9M	-4.9M	-6M	-7.9M	-13.1M	-10.3M	-2.6M

SEC Filings

CAPR - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 12, 2026	May 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 10, 2026	June 04, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 17, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 12, 2026	March 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 10, 2026	March 10, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 05, 2025	December 05, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 03, 2025	December 03, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 03, 2025	December 03, 2025	2025	View Filing

Showing 1 to 10 of 348 filings

Related Guides

Blog Categories

Continue your CAPR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.